Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:07:07 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:APTO - APTOSE BIOSCIENCES INC - https://aptose.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
APTO - QDEFUNCT1.71    51.609  2.3937Apr 01May 0515 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-05 07:00U:APTONews ReleaseAptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
2025-04-23 17:00U:APTONews ReleaseAptose Announces Auditor Not Standing for Re-Appointment
2025-04-23 07:30U:APTONews ReleaseAptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
2025-04-01 08:30U:APTONews ReleaseAptose Common Shares to Delist from Nasdaq as of April 2, 2025
2025-03-28 08:02U:APTONews ReleaseAptose Reports Year End 2024 Results and Corporate Highlights
2025-03-17 07:30U:APTONews ReleaseAptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
2025-02-20 07:32U:APTONews ReleaseAptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
2025-02-18 16:30U:APTONews ReleaseAptose Announces Reverse Share Split
2025-02-13 16:30U:APTONews ReleaseAptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
2025-02-12 07:00U:APTONews ReleaseAptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
2025-01-09 16:00U:APTONews ReleaseAptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
2024-12-19 16:05U:APTONews ReleaseAptose Announces Positive Decision by Nasdaq Hearings Panel
2024-12-12 10:15U:APTONews ReleaseAptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
2024-12-09 12:00U:APTONews ReleaseAptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
2024-12-03 07:30U:APTONews ReleaseAptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
2024-11-25 16:15U:APTONews ReleaseAptose Biosciences Inc. Announces Closing of $8 Million Public Offering
2024-11-22 08:00U:APTONews ReleaseAptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
2024-11-20 07:30U:APTONews ReleaseAptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
2024-11-08 16:01U:APTONews ReleaseAptose Reports Results for the Third Quarter 2024
2024-09-05 16:15U:APTONews ReleaseAptose Announces Results from Special Meeting of Shareholders